Christophe Hourioux

Dr. Christophe Hourioux


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
SESébastien Eymieux
Sébastien Eymieux
Rustem UzbekovRustem Uzbekov
Rustem Uzbekov
YRYves Rouillé
Yves Rouillé
EBEmmanuelle Blanchard
Emmanuelle Blanchard
CHChristophe Hourioux
Christophe Hourioux
PRPhilippe Roingeard
Philippe Roingeard
The mechanisms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) egress, similar to those of other coronaviruses, remain poorly understood. The virus buds in intracellular compartments and is therefore thought to be released by the biosynthetic secretory pathway. However, several studies have recently challenged this hypothesis. It has been suggested that coronaviruses, including SARS-CoV-2, use lysosomes for egress. In addition, a focused ion-beam scanning electron microscope (FIB/SEM) study suggested the existence of exit tunnels linking cellular compartments rich in viral particles to the extracellular space resembling those observed for the human immunodeficiency (HIV) in macrophages. Here, we analysed serial sections of Vero cells infected with SARS-CoV-2 by transmission electron microscopy (TEM). We found that SARS-CoV-2 was more likely to exit the cell in small secretory vesicles. Virus trafficking within the cells involves small vesicles, with each generally containing a single virus particle. These vesicles then fuse with the plasma membrane to release the virus into the extracellular space. This work sheds new light on the late stages of the SARS-CoV-2 infectious cycle of potential value for guiding the development of new antiviral strategies.

8 July 2020 in Viruses
Verified
Journal Article
Open access
PDF file
HRHugues de Rocquigny
Hugues de Rocquigny
VRVirgile Rat
Virgile Rat
FPFlorentin Pastor
Florentin Pastor
JDJean Luc Darlix
Jean Luc Darlix
CHChristophe Hourioux
Christophe Hourioux
PRPhilippe Roingeard
Philippe Roingeard
The morphogenesis of Hepatitis B Virus (HBV) viral particles is nucleated by the oligomerization of HBc protein molecules, resulting in the formation of an icosahedral capsid shell containing the replication-competent nucleoprotein complex made of the viral polymerase and the pre-genomic RNA (pgRNA). HBc is a phospho-protein containing two distinct domains acting together throughout the viral replication cycle. The N-terminal domain, (residues 1–140), shown to self-assemble, is linked by a short flexible domain to the basic C-terminal domain (residues 150–183) that interacts with nucleic acids (NAs). In addition, the C-terminal domain contains a series of phospho-acceptor residues that undergo partial phosphorylation and de-phosphorylation during virus replication. This highly dynamic process governs the homeostatic charge that is essential for capsid stability, pgRNA packaging and to expose the C-terminal domain at the surface of the particles for cell trafficking. In this review, we discuss the roles of the N-terminal and C-terminal domains of HBc protein during HBV morphogenesis, focusing on how the C-terminal domain phosphorylation dynamics regulate its interaction with nucleic acids throughout the assembly and maturation of HBV particles.

1 June 2020 in Journal of Molecular Biology
Verified
Journal Article
Closed access
VRVirgile Rat
Virgile Rat
XPXavier Pinson
Xavier Pinson
FSFlorian Seigneuret
Florian Seigneuret
SDStéphanie Durand
Stéphanie Durand
CHCharline Herrscher
Charline Herrscher
HRHugues de Rocquigny
Hugues de Rocquigny

14 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CHCharline Herrscher
Charline Herrscher
SESébastien Eymieux
Sébastien Eymieux
CGChristophe Gaborit
Christophe Gaborit
Helene BlascoHelene Blasco
Helene Blasco
JMJulien Marlet
Julien Marlet
CHChristophe Hourioux
Christophe Hourioux
Since the start of the COVID-19 pandemic, many studies have investigated the humoral response to SARS-CoV-2 during infection. Studies with native viral proteins constitute a first-line approach to assessing the overall immune response, but small peptides are an accurate and valuable tool for the fine characterization of B-cell epitopes, despite the restriction of this approach to the determination of linear epitopes. In this study, we used ELISA and peptides covering a selection of structural and non-structural SARS-CoV-2 proteins to identify key epitopes eliciting a strong immune response that could serve as a biological signature of disease characteristics, such as severity, in particular. We used 213 plasma samples from a cohort of patients well-characterized clinically and biologically and followed for COVID-19 infection. We found that patients developing severe disease had higher titers of antibodies mapping to multiple specific epitopes than patients with mild to moderate disease. These data are potentially important as they could be used for immunological profiling to improve our knowledge of the quantitative and qualitative characteristics of the humoral response in relation to patient outcome.